What is the 13F Pro Quality Score for TELA?

13F Pro ranks TELA Bio, Inc. (TELA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TELA's current score at https://13fpro.ai/research/TELA (free sign-up required for the full ranking).

Where does 13F Pro source TELA data?

All TELA Bio, Inc. fundamentals and ownership data come directly from SEC EDGAR. TELA Bio, Inc. files with the SEC under CIK 1561921. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TELA in?

TELA Bio, Inc. (TELA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TELA research updated on 13F Pro?

TELA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TELA Bio, Inc.(TELA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1561921 TELA stock profile & AI dashboard →

13F Pro Quality Score

24.9/100

Rank #2,567 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

76.8/100

Profitability

10.8/100

Balance Sheet

3.2/100

Earnings Quality

30.0/100

Free Cash Flow

9.8/100

Institutional Flow

6.7/100

Revenue Scale

15.0/100

Dilution Risk

26.7/100

TELA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for TELA Bio, Inc. (TELA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TELA at 24.9/100 on a 32-signal composite quality model, placing it at rank #2,567 of 2,879 stocks — the bottom half of the AI-ranked universe. TELA scores in the top quartile across revenue growth (76.8). Areas of concern include balance sheet strength (3.2) and institutional flow (6.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), TELA Bio, Inc. reports quarterly revenue of $19.1M, net income of $-12.3M, an operating margin of -55.2%. Top institutional holders of TELA by reported 13-F value include Essex Woodlands Management,, Nantahala Capital Management,, Stonepine Capital Management,, based on the most recent SEC filings. TELA trades on the Nasdaq exchange and files with the SEC under CIK 1561921. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TELA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TELA Bio, Inc. directly from SEC EDGAR. TELA Bio, Inc.'s 13F Pro composite quality score has ranged between 25 and 32 since 2022, currently 24.9 — a declining long-term trajectory across 24 quarterly and live scoring snapshots.

✦

Fun facts about TELA Bio, Inc.

Quirks, history, and lore behind TELA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the range of roughly $60–80 million — a true small-cap grinder — with a commercial focus on a single surgical category.
3
The History
Founded in the 2010s and built around technology licensed from academic research, it went public to fund the rollout of its first commercial product line.
4
The Secret
Its products are made from porcine (pig) tissue and a proprietary polymer matrix, designed to mimic how the body's own abdominal wall is structured.
5
The Lore
Its flagship product, OviTex, is a reinforced tissue matrix used in hernia repair — one of the most common surgical procedures performed worldwide.
6
The Giveaway
The name is literally a mashup of "tissue engineering" and "biologic" — a Pennsylvania med-tech shop stitching its way through the hernia repair market one OviTex implant at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$19.1M

Net Income

Q1 2026

$-12.3M

Free Cash Flow

Q1 2026

$-11.3M

Operating Margin

Q1 2026

-55.2%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+15.8% YoY

$80.3MFY 2025

FY22 $41.4MFY23 $58.5MFY24 $69.3MFY25 $80.3M

Net Income

-2.6% YoY

$-38.8MFY 2025

FY22 $-44.3MFY23 $-46.7MFY24 $-37.8MFY25 $-38.8M

Operating Income

+1.1% YoY

$-33.8MFY 2025

FY22 $-39.0MFY23 $-44.1MFY24 $-34.1MFY25 $-33.8M

EPS (Diluted)

+37.6% YoY

$-0.83FY 2025

FY22 $-2.72FY23 $-2.04FY24 $-1.33FY25 $-0.83

Total Assets

-6.0% YoY

$81.4MFY 2025

FY22 $67.9MFY23 $78.0MFY24 $86.6MFY25 $81.4M

Total Debt

+35.3% YoY

$55.7MFY 2025

FY22 $39.9MFY23 $40.5MFY24 $41.1MFY25 $55.7M

Op. Cash Flow

+32.2% YoY

$-28.2MFY 2025

FY22 $-40.7MFY23 $-40.9MFY24 $-41.6MFY25 $-28.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$80.3M +15.8%	$69.3M +18.6%	$58.5M +41.1%	$41.4M +40.6%	$29.5M +61.8%	$18.2M
Net Income	$-38.8M -2.6%	$-37.8M +19.0%	$-46.7M -5.3%	$-44.3M -33.1%	$-33.3M -15.6%	$-28.8M
Operating Income	$-33.8M +1.1%	$-34.1M +22.6%	$-44.1M -13.0%	$-39.0M -32.4%	$-29.5M -16.5%	$-25.3M
EPS (Diluted)	$-0.83 +37.6%	$-1.33 +34.8%	$-2.04 +25.0%	$-2.72 -18.3%	$-2.30 -3.1%	$-2.23
Total Assets	$81.4M -6.0%	$86.6M +10.9%	$78.0M +15.0%	$67.9M +8.5%	$62.5M -27.7%	$86.5M
Total Debt	$55.7M +35.3%	$41.1M +1.5%	$40.5M +1.5%	$39.9M +26.8%	$31.5M +2.2%	$30.8M
Operating Cash Flow	$-28.2M +32.2%	$-41.6M -1.8%	$-40.9M -0.3%	$-40.7M -33.9%	$-30.4M -24.4%	$-24.5M

AI Insight: TELA Financial Trends

TELA is burning cash despite modest revenue stabilization; operating losses persist and leverage has increased 37% since Q2 2024.

• Revenue flat at $19–21M across last 6 quarters; Q1 2026 dipped to $19M. No meaningful growth trajectory evident.

• Operating cash outflow improved from $-11M (Q2 2024) to $-5M (Q4 2025), but reversed sharply to $-11M in Q1 2026.

• Total debt rose from $41M (Q2 2024) to $56M (Q4 2025–Q1 2026), a 37% increase. Equity eroded to $-5M (Q1 2026).

⚠ Negative equity of $-5M in Q1 2026 signals balance-sheet stress. Liabilities now exceed assets.

⚠ Operating losses remain structural at $-7M to $-12M per quarter. No path to profitability apparent in current data.

⚠ Q1 2026 cash burn ($-11M) matches worst quarters in dataset. Recent improvement trend has stalled.

AI Insight: TELA Ratio Trends

Operating margin deteriorated sharply to -55.2% in Q1 2026, reversing nine months of sequential improvement and signaling a significant operational setback.

• Operating margin improved from -71.9% in Q2 2024 to -31.9% in Q4 2025, but collapsed back to -55.2% in Q1 2026—largest quarterly decline in dataset.

• ROA swung from -83.7% in Q2 2024 to -44.4% in Q4 2025, but deteriorated to -70.2% in Q1 2026, erasing four quarters of gains.

• Debt-to-equity spiked to 26.65x in Q3 2025 before moderating; capital structure remains unstable and highly leveraged.

⚠ Q1 2026 NPM at -64.4%—worst since Q2 2024—suggests cost structure deterioration or revenue cliff unrelated to gross margin.

⚠ ROIC collapsed 40.2pp from Q4 2025 (-42.9%) to Q1 2026 (-83.1%), indicating severe capital inefficiency in latest quarter.

Get alerted when TELA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TELA Bio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TELA

Essex Woodlands Management, Inc.
$4.8M7,714,709 sh
Nantahala Capital Management, LLC
$3.2M5,144,114 sh
Stonepine Capital Management, LLC
$1.6M2,617,252 sh
SILVERARC CAPITAL MANAGEMENT, LLC
$1.4M2,259,312 sh
VANGUARD CAPITAL MANAGEMENT LLC
$955.2K1,540,624 sh
DAFNA Capital Management LLC
$893.4K1,441,029 sh
PERKINS CAPITAL MANAGEMENT INC
$879.4K1,418,328 sh
UBS Group AG
$656.9K1,059,524 sh
CITIGROUP INC
$465.0K750,000 sh
Nantahala Capital Management, LLC
$465.0K750,000 sh

Fund	Value	Shares
Essex Woodlands Management, Inc.	$4.8M	7,714,709
Nantahala Capital Management, LLC	$3.2M	5,144,114
Stonepine Capital Management, LLC	$1.6M	2,617,252
SILVERARC CAPITAL MANAGEMENT, LLC	$1.4M	2,259,312
VANGUARD CAPITAL MANAGEMENT LLC	$955.2K	1,540,624
DAFNA Capital Management LLC	$893.4K	1,441,029
PERKINS CAPITAL MANAGEMENT INC	$879.4K	1,418,328
UBS Group AG	$656.9K	1,059,524
CITIGROUP INC	$465.0K	750,000
Nantahala Capital Management, LLC	$465.0K	750,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TELA on your watchlist

Track score changes the day TELA Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TELA a good stock to buy?

13F Pro's AI-powered analysis of TELA Bio, Inc. (TELA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TELA are available on the TELA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TELA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TELA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TELA Bio, Inc.'s investment landscape.